Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 02.06.2025 1 AJR Am J Roentgenol 1 Am J Pathol 4 Biochem Biophys Res Commun 4 BMC Cancer 6 BMC Gastroenterol 1 Br J Surg 1 Dig Dis 2 Endoscopy 1 Eur Radiol 1 Gastroenterology 1 J Gastroenterol 5 J Hepatol 1 Oncogene 10 PLoS One 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LI L, Burgio MD, Fetzer DT, Ferraioli G, et al
   Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Diagnosis-AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2025 May 28. doi: 10.2214/AJR.25.32813.
   PubMed         Abstract available
   
   

   
   Am J Pathol

2. ZHONG H, Liu C, Huang Z, Tan P, et al
   Crosstalk between Hepatic Stellate Cells and Hepatic Macrophages in Metabolic Dysfunction-Associated Steatohepatitis.
   Am J Pathol. 2025;195:1040-1056.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

3. CHEN C, Zhang M, Ma XH, Wang CM, et al
   Hepatic stellate cell-derived Delta-like 1 is dispensable for injury-induced liver fibrosis.
   Biochem Biophys Res Commun. 2025;771:152011.
   PubMed         Abstract available
   
   
4. ZHAO Y, Xie L, Liu B, Deng Y, et al
   Novel insight into the role of Src family kinases in hepatocellular carcinoma and therapeutic potential.
   Biochem Biophys Res Commun. 2025;772:151970.
   PubMed         Abstract available
   
   
5. SHI Q, Ren L, Papineau K, Yang X, et al
   Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations.
   Biochem Biophys Res Commun. 2025;773:152075.
   PubMed         Abstract available
   
   
6. KOGA T, Hiromura M, Song Y, Zhao S, et al
   Selenium binding protein 1 (SBP1) suppresses fructose-induced metabolic dysfunction-associated steatotic liver disease.
   Biochem Biophys Res Commun. 2025;770:152013.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. LIU J, Zhang T, Gao Y, Ji D, et al
   Causal role of immune cells in primary liver cancer: a mendelian randomization study.
   BMC Cancer. 2025;25:928.
   PubMed         Abstract available
   
   
8. ZHANG X, Huang XT, Xie JZ, Fu AQ, et al
   Prognostic significance of the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma after radical resection: an IPTW propensity-score analysis.
   BMC Cancer. 2025;25:930.
   PubMed         Abstract available
   
   
9. MU Z, Su J, Yi J, Fan R, et al
   A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.
   BMC Cancer. 2025;25:941.
   PubMed         Abstract available
   
   
10. GENG D, Lv N, Miao Y
    Pyogenic liver abscess following biliary stent placement in pancreatic cancer patients: a retrospective case series.
    BMC Cancer. 2025;25:965.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

11. ZHANG M, Yuan Y, Wang C, Huang Y, et al
    Aggregate index of systemic inflammation tied to increased fatty liver disease risk: insights from NHANES data.
    BMC Gastroenterol. 2025;25:399.
    PubMed         Abstract available
    
    
12. HUANG Z, Ling W, Lyu G, Xu S, et al
    Correlation analyses of ultrasonographic and histopathological characteristics of porta hepatis lymph nodes in biliary atresia.
    BMC Gastroenterol. 2025;25:398.
    PubMed         Abstract available
    
    
13. XIANG Y, Mao W
    Neutrophil-derived ratios as predictors of short-term mortality in HBV-associated decompensated cirrhosis.
    BMC Gastroenterol. 2025;25:404.
    PubMed         Abstract available
    
    
14. LV M, Shafagh G, Yu S
    Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
    BMC Gastroenterol. 2025;25:407.
    PubMed         Abstract available
    
    
15. DENG L, Sun J, Wang J, Duan X, et al
    Comprehensive analysis of risk factors and nomogram development for predicting hepatic metastasis following radical resection of adenocarcinoma of the esophagogastric junction.
    BMC Gastroenterol. 2025;25:409.
    PubMed         Abstract available
    
    
16. WANG J, He W, Cai X, Hu Z, et al
    Relative fat mass and risk of metabolic dysfunction associated steatotic liver disease and severe hepatic steatosis in U.S. adults: analysis of NHANES 2017-2020 data.
    BMC Gastroenterol. 2025;25:410.
    PubMed         Abstract available
    
    

    
    Br J Surg

17. BARTHOLOMA WC, Gilg S, Lundberg P, Larsen PN, et al
    Magnetic resonance-derived hepatic uptake index improves the identification of patients at risk of severe post-hepatectomy liver failure.
    Br J Surg. 2025;112:znaf103.
    PubMed         Abstract available
    
    

    
    Dig Dis

18. LIU JK, Chien N, Chong C, Barnett S, et al
    Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the United States.
    Dig Dis. 2025 May 28:1-20. doi: 10.1159/000546600.
    PubMed         Abstract available
    
    

    
    Endoscopy

19. MURABAYASHI T, Sugimoto S
    Troubleshooting for perforation due to proximal metal stent displacement in endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    
20. NAGASHIMA K, Inaba Y, Kashima K, Kunogi Y, et al
    Endoscopic injection sclerotherapy with ligation for esophageal varices using single-use endoscope: Report of a video case.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur Radiol

21. OCAL O, Zech CJ, Bali MA, Pasquier D, et al
    Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR.
    Eur Radiol. 2025 May 23. doi: 10.1007/s00330-025-11699.
    PubMed         Abstract available
    
    

    
    Gastroenterology

22. MCGETTIGAN B, Hernandez-Tejero M, Malhi H, Shah V, et al
    Immune Dysfunction and Infection Risk in Advanced Liver Disease.
    Gastroenterology. 2025;168:1085-1100.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

23. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    PubMed         Abstract available
    
    

    
    J Hepatol

24. CHEW V
    Harnessing spatial immunity to predict recurrence in hepatocellular carcinoma.
    J Hepatol. 2025 May 27:S0168-8278(25)00239-9. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
25. ENGELMANN C
    Rethinking hepatic encephalopathy: Gut microbes, neurotoxins and the therapeutic horizon.
    J Hepatol. 2025 May 27:S0168-8278(25)00295-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
26. ZHANG X, Shen J, Man K, Chu ESH, et al
    Corrigendum to "CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis" [J Hepatol (2014) 61:1365-75].
    J Hepatol. 2025 May 24:S0168-8278(25)00157-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
27. RUDLER M
    Autologous macrophage therapy for compensated cirrhosis, some hope at the horizon.
    J Hepatol. 2025 May 23:S0168-8278(25)00248-X. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
28. HIRSCH TZ
    Immune exclusion in hepatoblastoma: is beta-catenin to blame again?
    J Hepatol. 2025 May 21:S0168-8278(25)02203-2. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    Oncogene

29. GENG X, Li M, Zhang L, Cai Y, et al
    P5CS deacetylation mediated by SIRT2 facilitates tumor growth by enhancing mitochondrial respiration in hepatocellular carcinoma.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03456.
    PubMed         Abstract available
    
    

    
    PLoS One

30. ESSAM MYN, Kouam AF, Fepa AGK, Seukep AJ, et al
    Serological evidence and factors associated to liver damage in malaria-typhoid infected patients consulting in two health facilities, Yaounde-Cameroon.
    PLoS One. 2025;20:e0319547.
    PubMed         Abstract available
    
    
31. WEI W, Gan Y, Zhang X, Chen Y, et al
    Exploring the level of metabolic reprogramming and the role of prognostic factor SF3A3 in hepatocellular carcinoma through integrated single-cell landscape analysis.
    PLoS One. 2025;20:e0323559.
    PubMed         Abstract available
    
    
32. SCHACHTSCHNEIDER KM, Redlon LN, Lokken RP, Huang YH, et al
    Epigenetic regulation of individual components of combined hepatocellular-cholangiocarcinoma.
    PLoS One. 2025;20:e0324145.
    PubMed         Abstract available
    
    
33. BEI X, Zhao C, Liu J, Cao J, et al
    PCYT2 overexpression induces mitochondrial damage and promotes apoptosis in hepatocellular carcinoma cells.
    PLoS One. 2025;20:e0323974.
    PubMed         Abstract available
    
    
34. LU H, Mao Z, Zheng M, Zhang M, et al
    Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning.
    PLoS One. 2025;20:e0324972.
    PubMed         Abstract available
    
    
35. MA J, Xu R, Li R, Fu Y, et al
    Integration of bioinformatics and identification of the role of m6A genes in NAFLD.
    PLoS One. 2025;20:e0321757.
    PubMed         Abstract available
    
    
36. ZHAO K, Hu HT, Li HL, Cheng HT, et al
    Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.
    PLoS One. 2025;20:e0323829.
    PubMed         Abstract available
    
    
37. JIANG H, Qin C, Xu YM
    Feasibility of shear wave elastography for assessing steatosis in early-stage non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0324637.
    PubMed         Abstract available
    
    
38. LU Y, Lin J, Lu Y, Lin L, et al
    Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0323023.
    PubMed         Abstract available
    
    
39. HE Y, Chang Y, Liu X, Li Y, et al
    Associations of flavonoid intakes with metabolic dysfunction-associated steatotic liver disease in US adults.
    PLoS One. 2025;20:e0322797.
    PubMed         Abstract available
    
    

    
    Transplant Proc

40. SINAN EFE Y, Ahmet A, Ebru T, Tolga S, et al
    Echinococcal Liver Infections: Comparing Transplant Strategies for Granulosus and Alveolaris.
    Transplant Proc. 2025;57:916-921.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.